Non-Current Liabilities
Long-Term Debt
Moderna Long-Term Debt remained flat by 0.0% to $590M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026May 1, 2026
How to read this metric
Lower debt levels generally indicate lower financial risk, though some debt is often used to fund growth in capital-intensive industries.
Detailed definition
Long-term debt includes all interest-bearing financial obligations with maturities extending beyond one year, such as bo...
Peer comparison
Standard metric for all companies; biotech firms often maintain lower debt levels unless they are highly mature or cash-flow positive.
Metric ID:
long_term_debtHistorical Data
3 periods
| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $0 | $590M | $590M |
| QoQ Change | — | — | +0.0% |
Range$0 – $590M
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Moderna's long-term debt?
- Moderna (MRNA) reported long-term debt of $590M in Q1 2026.
- What does long-term debt mean?
- Debt obligations that are due to be paid back after more than one year.